...
首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Eupatilin attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 ex pression in diabetic rat kidney
【24h】

Eupatilin attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 ex pression in diabetic rat kidney

机译:Eupatilin通过上调糖尿病大鼠肾脏中基质金属蛋白酶9的表达来减轻糖尿病肾病

获取原文
           

摘要

Purpose: To evaluate the nephro-protective effect of eupatilin in diabetic nephropathic (DN) rats. Method: Diabetes was induced by intraperitoneal administration of streptozotocin (STZ, 55 mg/kg) and confirmed by fasting blood glucose results, while DN was determined by measuring serum urea and creatinine levels on day 40 after STZ administration. The eupatilin-treated group received eupatilin at 50 and 100 mg/kg, p.o. for 20 days, after which blood levels of some biochemical parameters, glomerulosclerosis index, eosinophilic cast index, and ex pression of MMP-9 were determined using standard procedures. Results: Treatment with eupatilin significantly decreased serum levels of glucose, creatinine and urea, and increased creatinine clearance, compared to the negative control group. Moreover, eupatilin attenuated changes in kidney histopathology, and significantly enhanced the ex pression of MMP-9 in the kidney tissues of the DN rats, relative to negative control group. Conclusion: These results indicate that eupatilin attenuates renal failure in STZ-induced DN rats by upregulating the ex pression of MMP-9.
机译:目的:评价依帕替林对糖尿病肾病性肾病(DN)大鼠的肾保护作用。方法:腹膜内施用链脲佐菌素(STZ,55 mg / kg)可诱发糖尿病,并通过空腹血糖结果予以证实;而在STZ施用后第40天,通过测定血清尿素和肌酐水平来确定DN。依帕替林治疗组的p.o剂量为50和100 mg / kg。持续20天,然后使用标准程序测定某些生化参数,肾小球硬化指数,嗜酸性铸型指数和MMP-9的表达水平。结果:与阴性对照组相比,用依匹替林治疗可显着降低血清葡萄糖,肌酐和尿素水平,并增加肌酐清除率。此外,相对于阴性对照组,依帕替林减轻了肾脏组织病理学的改变,并显着增强了DN大鼠肾脏组织中MMP-9的表达。结论:这些结果表明,依帕替林通过上调MMP-9的表达来减轻STZ诱导的DN大鼠的肾衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号